SCHEMBL299671

SCHEMBL299671

CN(C)C1CCc2c(cccc2-c2ccccc2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 20/20 1.00
HTR7 P34969 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26690441 1.00 HTR1A (1.00) HTR1AHTR7
Hydrochloric Acid SCHEMBL26612713 0.98 HTR1A (0.97) HTR1AHTR7
SCHEMBL16687760 0.86 HTR1A (0.75) HTR1AHTR7
SCHEMBL9945843 0.85 HTR1A (1.00) HTR1AHTR7
SCHEMBL3311285 0.84 HTR1A (0.71) HTR1AHTR7
SCHEMBL9945840 0.83 HTR1A (1.00) HTR1AHTR7
SCHEMBL9945842 0.83 HTR1A (1.00) HTR1AHTR7
SCHEMBL23425387 0.82 HTR1A (1.00) HTR1AHTR7
SCHEMBL17274574 0.82 HTR1A (1.00) HTR1AHTR7
SCHEMBL30831827 0.82 HTR1A (1.00) HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4200287-A2 SEROTONIN RECEPTOR MODULATORS Northeastern University (US) 2023-06-28 EP disclosed
WO-2022040395-A2 SEROTONIN RECEPTOR MODULATORS NORTHEASTERN UNIVERSITY (US) 2022-02-24 WO disclosed
US-11021435-B2 Serotonin receptor-targeting compounds and methods NORTHEASTERN UNIVERSITY (US) 2021-06-01 US disclosed
US-10017458-B2 Therapeutic tetrahydronaphthalene compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2018-07-10 US disclosed
US-10017458-B2 Therapeutic tetrahydronaphthalene compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2018-07-10 US disclosed
US-10017458-B2 Therapeutic tetrahydronaphthalene compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2018-07-10 US disclosed
US-20170081273-A1 Serotonin Receptor-Targeting Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-03-23 US disclosed
US-20170081273-A1 Serotonin Receptor-Targeting Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-03-23 US disclosed
US-9422229-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-08-23 US disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 US disclosed
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 US disclosed
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 US disclosed
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 US disclosed
EP-2427183-A2 THERAPEUTIC COMPOUNDS University of Florida Research Foundation, Inc. (US) 2012-03-14 EP disclosed
US-20100305212-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-12-02 US disclosed
WO-2010129048-A2 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-11-11 WO disclosed
WO-2010129048-A2 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-11-11 WO disclosed
EP-2164324-A1 THERAPEUTIC COMPOUNDS University Of Florida Research Foundation (US) 2010-03-24 EP disclosed
WO-2009061436-A1 COMPOUND FOR ACTIVATING 5-HT2C RECEPTORS IN COMBINATION WITH AN AMPHETAMINE COMPOUND UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2009-05-14 WO disclosed
WO-2008156707-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149693-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 HTR1A 13/4885HTR7 22/4885
US-10017458-B2 Therapeutic tetrahydronaphthalene compounds HTR2C, HTR2A, HTR3C HTR1A 9/4885HTR7 22/4885
US-20150315127-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 HTR1A 13/4885HTR7 22/4885
US-11021435-B2 Serotonin receptor-targeting compounds and methods HTR1A, HTR2C, HTR7 HTR1A 1/4885HTR7 3/4885
US-20170081273-A1 Serotonin Receptor-Targeting Compounds and Methods HTR1A, HTR2C, HTR7 HTR1A 1/4885HTR7 3/4885
US-20100305212-A1 THERAPEUTIC COMPOUNDS HTR2C, HTR3B, HTR2A HTR1A 12/4885HTR7 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.